Literature DB >> 33499448

4-Aminopyridine: A Single-Dose Diagnostic Agent to Differentiate Axonal Continuity in Nerve Injuries.

Anagha A Gurjar1, Kristen M Manto1, Juan A Estrada2, Marc Kaufman2, Dongxiao Sun3, M A Hassan Talukder1, John C Elfar1.   

Abstract

INTRODUCTION: Traumatic peripheral nerve injuries (TPNIs) are increasingly prevalent in battlefield trauma, and the functional recovery with TPNIs depends on axonal continuity. Although the physical examination is the main tool for clinical diagnosis with diagnostic work up, there is no diagnostic tool available to differentiate nerve injuries based on axonal continuity. Therefore, treatment often relies on "watchful waiting," and this leads to muscle weakness and further reduces the chances of functional recovery. 4-aminopyridine (4-AP) is clinically used in multiple sclerosis patients for walking performance improvement. Preliminary results in conscious mice suggested a diagnostic role of 4-AP in distinguishing axonal continuity. In this study, we thought to evaluate the diagnostic potential of 4-AP on the axonal continuity in unawake/sedated animals.
MATERIALS AND METHODS: Rat sciatic nerve crush and transection injuries were used in this study. Briefly, rats were anesthetized with isoflurane and mechanically ventilated with oxygen-balanced vaporized isoflurane. Sciatic nerve and triceps surae muscles were exposed by blunt dissection, and a stimulating electrode was placed under a sciatic nerve proximal to the crush injury. A force transducer measured muscle tension response to electrical stimulation of sciatic nerve. Muscle response was measured before crush, after crush, and 30 minutes after systemic 4-AP (150 µg/kg) or local (4-AP)-poly(lactide-co-glycolide)-b-poly(ethylene glycol)-b-poly(lactide-co-glycolide) (PLGA-PEG) treatment.
RESULTS: We found that both crush and transection injuries in sciatic nerve completely abolished muscle response to electrical stimulation. Single dose of systemic 4-AP and local (4-AP)-PLGA-PEG treatment with crush injury significantly restored muscle responses to electrical stimulation after 30 minutes of administration. However, systemic 4-AP treatment had no effect on muscle response after nerve transection. These results clearly demonstrate that 4-AP can restore nerve conduction and produce muscle response within minutes of administration only when there is a nerve continuity, even in the sedated animal.
CONCLUSIONS: We conclude that 4-AP could be a promising diagnostic agent in differentiating TPNI based on axonal continuity. © The Association of Military Surgeons of the United States 2021. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33499448      PMCID: PMC7832841          DOI: 10.1093/milmed/usaa310

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  27 in total

1.  Volatile anesthetic effects on glutamate versus GABA release from isolated rat cortical nerve terminals: basal release.

Authors:  Robert I Westphalen; Hugh C Hemmings
Journal:  J Pharmacol Exp Ther       Date:  2005-09-20       Impact factor: 4.030

2.  Potassium channel blocker, 4-aminopyridine-3-methanol, restores axonal conduction in spinal cord of an animal model of multiple sclerosis.

Authors:  Gary Leung; Wenjing Sun; Sarah Brookes; Daniel Smith; Riyi Shi
Journal:  Exp Neurol       Date:  2010-11-17       Impact factor: 5.330

3.  Polyethylene glycol solutions rapidly restore and maintain axonal continuity, neuromuscular structures, and behaviors lost after sciatic nerve transections in female rats.

Authors:  Michelle Mikesh; Cameron L Ghergherehchi; Robert Louis Hastings; Amir Ali; Sina Rahesh; Karthik Jagannath; Dale R Sengelaub; Richard C Trevino; David M Jackson; George D Bittner
Journal:  J Neurosci Res       Date:  2018-04-16       Impact factor: 4.164

4.  Clinically Relevant Levels of 4-Aminopyridine Strengthen Physiological Responses in Intact Motor Circuits in Rats, Especially After Pyramidal Tract Injury.

Authors:  Anil Sindhurakar; Asht M Mishra; Disha Gupta; Jennifer F Iaci; Tom J Parry; Jason B Carmel
Journal:  Neurorehabil Neural Repair       Date:  2017-01-20       Impact factor: 3.919

5.  Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension.

Authors:  K J Smith; P A Felts; G R John
Journal:  Brain       Date:  2000-01       Impact factor: 13.501

6.  4-Aminopyridine attenuates muscle atrophy after sciatic nerve crush injury in mice.

Authors:  Li Yue; M A Hassan Talukder; Anagha Gurjar; Jung Il Lee; Mark Noble; Robert T Dirksen; Joe Chakkalakal; John C Elfar
Journal:  Muscle Nerve       Date:  2019-05-30       Impact factor: 3.217

7.  4-Aminopyridine as a Single Agent Diagnostic and Treatment for Severe Nerve Crush Injury.

Authors:  Mark Noble; Kuang-Ching Chris Tseng; Haiyan Li; John C Elfar
Journal:  Mil Med       Date:  2019-03-01       Impact factor: 1.437

Review 8.  Musculoskeletal Injuries in Iraq and Afghanistan: Epidemiology and Outcomes Following a Decade of War.

Authors:  Philip J Belmont; Brett D Owens; Andrew J Schoenfeld
Journal:  J Am Acad Orthop Surg       Date:  2016-06       Impact factor: 3.020

9.  Inhibition by volatile anesthetics of endogenous glutamate release from synaptosomes by a presynaptic mechanism.

Authors:  M Schlame; H C Hemmings
Journal:  Anesthesiology       Date:  1995-06       Impact factor: 7.892

10.  4-Aminopyridine promotes functional recovery and remyelination in acute peripheral nerve injury.

Authors:  Kuang-Ching Tseng; Haiyan Li; Andrew Clark; Leigh Sundem; Michael Zuscik; Mark Noble; John Elfar
Journal:  EMBO Mol Med       Date:  2016-12-01       Impact factor: 12.137

View more
  1 in total

1.  (4-Aminopyridine)-PLGA-PEG as a Novel Thermosensitive and Locally Injectable Treatment for Acute Peripheral Nerve Injury.

Authors:  Kristen M Manto; Prem Kumar Govindappa; Daniele Parisi; Zara Karuman; Brandon Martinazzi; John P Hegarty; M A Hassan Talukder; John C Elfar
Journal:  ACS Appl Bio Mater       Date:  2021-04-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.